ABSTRACT
The emerging SARS-CoV and SARS-CoV-2 belong to the family of "common cold" RNA coronaviruses, and they are responsible for the 2003 epidemic and the current pandemic with over 6.3 M deaths worldwide. The ORF3a gene is conserved in both viruses and codes for the accessory protein ORF3a, with unclear functions, possibly related to viral virulence and pathogenesis. The tyrosine-based YXXΦ motif (Φ: bulky hydrophobic residue-L/I/M/V/F) was originally discovered to mediate clathrin-dependent endocytosis of membrane-spanning proteins. Many viruses employ the YXXΦ motif to achieve efficient receptor-guided internalisation in host cells, maintain the structural integrity of their capsids and enhance viral replication. Importantly, this motif has been recently identified on the ORF3a proteins of SARS-CoV and SARS-CoV-2. Given that the ORF3a aa sequence is not fully conserved between the two SARS viruses, we aimed to map in silico structural differences and putative sequence-driven alterations of regulatory elements within and adjacently to the YXXΦ motifs that could predict variations in ORF3a functions. Using robust bioinformatics tools, we investigated the presence of relevant post-translational modifications and the YXXΦ motif involvement in protein-protein interactions. Our study suggests that the predicted YXXΦ-related features may confer specific-yet to be discovered-functions to ORF3a proteins, significant to the new virus and related to enhanced propagation, host immune regulation and virulence.
Subject(s)
COVID-19 , Severe acute respiratory syndrome-related coronavirus , Host Microbial Interactions , Humans , Peptides , Severe acute respiratory syndrome-related coronavirus/genetics , SARS-CoV-2ABSTRACT
In the absence of a molecule that would collectively inhibit both metallo-ß-lactamases and serine-reactive carbapenemases, containment of their genes is the main weapon currently available for confronting carbapenem resistance in hospitals. Cost-effective methodologies rapidly detecting carbapenemase-producing enterobacteria (CPE) would facilitate such measures. Herein, a low-cost CPE detection method was developed that was based on the direct colorimetry of the yellow shift caused by the accumulation of diketopiperazines-products of the acid-catalyzed imipenem oligomerization-induced by carbapenemase action on dense solutions of imipenem/cilastatin. The reactions were studied by spectrophotometry in the visible spectrum using preparations of ß-lactamases from the four molecular classes. The effects of various buffers on reaction mixtures containing the potent carbapenemases NDM-1 and NMC-A were monitored at 405 nm. Optimal conditions were used for the analysis of cell suspensions, and the assay was evaluated using 66 selected enterobacteria, including 50 CPE as well as 16 carbapenemase-negative strains overexpressing other ß-lactamases. The development of the yellow color was specific for carbapenemase-containing enzyme preparations, and the maximum intensity was achieved in acidic or unbuffered conditions in the presence of zinc. When applied on bacterial cell suspensions, the assay could detect CPE with 98% sensitivity and 100% specificity, with results being comparable to those obtained with the Carba NP technique. Direct colorimetry of carbapenemase-induced imipenem decomposition required minimum reagents while exhibiting high accuracy in detecting CPE. Therefore, it should be considered for screening purposes after further clinical evaluation. IMPORTANCE Currently, the spread of multidrug-resistant (MDR) carbapenemase-producing enterobacteria (CPE), mostly in the clinical setting, is among the most pressing public health problems worldwide. In order to effectively control CPE, use of reliable and affordable methods detecting carbapenemase genes or the respective ß-lactamases is of vital importance. Herein, we developed a novel method, based on a previously undescribed phenomenon, that can detect CPE with few reagents by direct colorimetry of bacterial suspensions and imipenem/cilastatin mixtures.
Subject(s)
Enterobacteriaceae , Imipenem , Anti-Bacterial Agents/pharmacology , Bacterial Proteins/genetics , Cilastatin/pharmacology , Colorimetry , Cost-Benefit Analysis , Imipenem/pharmacology , Microbial Sensitivity Tests , Suspensions , beta-Lactamases/geneticsABSTRACT
The timely and accurate detection of carbapenemase-producing Enterobacterales (CPE) is imperative to manage this worldwide problem in an effective fashion. Herein we addressed the question of whether the protons produced during imipenem hydrolysis could be detected using an ion sensitive field effect transistor (ISFET). Application of the methodology on enzyme preparations showed that the sensor is able to detect carbapenemases of the NDM, IMP, KPC and NMC-A types at low nanomolar concentrations while VIM and OXA-48 responded at levels above 100 nM. Similar results were obtained when CPE cell suspensions were tested; NDM, IMP, NMC-A and KPC producers caused fast reductions of the output potential. Reduction rates with VIM-type and especially OXA-48 producing strains were significantly lower. Based on results with selected CPEs and carbapenemase-negative enterobacteria, a threshold of 10 mV drop at 30 min was set. Applying this threshold, the method exhibited 100% sensitivity for NDM, IMP and KPC and 77.3% for VIM producers. The OXA-48-positive strains failed to pass the detection threshold. A wide variety of carbapenemase-negative control strains were all classified as negative (100% specificity). In conclusion, an ISFET-based approach may have the potential to be routinely used for non OXA-48-like CPE detection in the clinical laboratory.
Subject(s)
Bacterial Proteins/analysis , Bacterial Typing Techniques , Enterobacteriaceae , Transistors, Electronic , beta-Lactamases/analysis , Electrochemical Techniques , Enterobacteriaceae/classification , Enterobacteriaceae/enzymology , HumansABSTRACT
Leishmaniases are complex vector-borne diseases caused by intracellular parasites of the genus Leishmania. The visceral form of the disease affects both humans and canids in tropical, subtropical, and Mediterranean regions. One health approach has suggested that controlling zoonotic visceral leishmaniasis (ZVL) could have an impact on the reduction of the human incidence of visceral leishmaniasis (VL). Despite the fact that a preventive vaccination could help with leishmaniasis elimination, effective vaccines that are able to elicit protective immune responses are currently lacking. In the present study, we designed a chimeric multi-epitope protein composed of multiple CD8+ and CD4+ T cell epitopes which were obtained from six highly immunogenic proteins previously identified by an immunoproteomics approach, and the N-termini of the heparin-binding hemagglutinin (HBHA) of Mycobacterium tuberculosis served as an adjuvant. A preclinical evaluation of the candidate vaccine in BALB/c mice showed that when it was given along with the adjuvant Addavax it was able to induce strong immune responses. Cellular responses were dominated by the presence of central and effector multifunctional CD4+ and CD8+ T memory cells. Importantly, the vaccination reduced the parasite burden in both short-term and long-term vaccinated mice challenged with Leishmania infantum. Protection was characterized by the continuing presence of IFN-γ+TNFα+-producing CD8+ and CD4+ T cells and increased NO levels. The depletion of CD8+ T cells in short-term vaccinated mice conferred a significant loss of protection in both target organs of the parasite, indicating a significant involvement of this population in the protection against L. infantum challenge. Thus, the overall data could be considered to be a proof-of-concept that the design of efficacious T cell vaccines with the help of reverse vaccinology approaches is possible.
ABSTRACT
Carbapenemases are the main cause of carbapenem resistance in Gram-negative bacteria. How ß-lactamases with weak carbapenemase activity, such as the OXA-10-type class D ß-lactamases, contribute to anti-bacterial drug resistance is unclear. OXA-655 is a T26M and V117L OXA-10 variant, recently identified from hospital wastewater. Despite exhibiting stronger carbapenemase activity towards ertapenem (ETP) and meropenem (MEM) in Escherichia coli, OXA-655 exhibits reduced activity towards oxyimino-substituted ß-lactams like ceftazidime. Here, we have solved crystal structures of OXA-10 in complex with imipenem (IPM) and ETP, and OXA-655 in complex with MEM in order to unravel the structure-function relationship and the impact of residue 117 in enzyme catalysis. The new crystal structures show that L117 is situated at a critical position with enhanced Van der Waals interactions to L155 in the omega loop. This restricts the movements of L155 and could explain the reduced ability for OXA-655 to bind a bulky oxyimino group. The V117L replacement in OXA-655 makes the active site S67 and the carboxylated K70 more water exposed. This could affect the supply of new deacylation water molecules required for hydrolysis and possibly the carboxylation rate of K70. But most importantly, L117 leaves more space for binding of the hydroxyethyl group in carbapenems. In summary, the crystal structures highlight the importance of residue 117 in OXA-10 variants for carbapenemase activity. This study also illustrates the impact of a single amino acid substitution on the substrate profile of OXA-10 and the evolutionary potential of new OXA-10 variants.
Subject(s)
Bacterial Proteins/metabolism , beta-Lactamases/metabolism , Bacterial Proteins/chemistry , Escherichia coli/enzymology , Molecular Dynamics Simulation , Molecular Structure , beta-Lactamases/chemistryABSTRACT
BACKGROUND: MBLs form a large and heterogeneous group of bacterial enzymes conferring resistance to ß-lactam antibiotics, including carbapenems. A large environmental reservoir of MBLs has been identified, which can act as a source for transfer into human pathogens. Therefore, structural investigation of environmental and clinically rare MBLs can give new insights into structure-activity relationships to explore the role of catalytic and second shell residues, which are under selective pressure. OBJECTIVES: To investigate the structure and activity of the environmental subclass B1 MBLs MYO-1, SHD-1 and ECV-1. METHODS: The respective genes of these MBLs were cloned into vectors and expressed in Escherichia coli. Purified enzymes were characterized with respect to their catalytic efficiency (kcat/Km). The enzymatic activities and MICs were determined for a panel of different ß-lactams, including penicillins, cephalosporins and carbapenems. Thermostability was measured and structures were solved using X-ray crystallography (MYO-1 and ECV-1) or generated by homology modelling (SHD-1). RESULTS: Expression of the environmental MBLs in E. coli resulted in the characteristic MBL profile, not affecting aztreonam susceptibility and decreasing susceptibility to carbapenems, cephalosporins and penicillins. The purified enzymes showed variable catalytic activity in the order of <5% to â¼70% compared with the clinically widespread NDM-1. The thermostability of ECV-1 and SHD-1 was up to 8°C higher than that of MYO-1 and NDM-1. Using solved structures and molecular modelling, we identified differences in their second shell composition, possibly responsible for their relatively low hydrolytic activity. CONCLUSIONS: These results show the importance of environmental species acting as reservoirs for MBL-encoding genes.
Subject(s)
Escherichia coli , beta-Lactamases , Anti-Bacterial Agents/pharmacology , Carbapenems , Escherichia coli/genetics , Humans , Microbial Sensitivity Tests , beta-Lactamases/geneticsABSTRACT
While carbapenem resistance in Gram-negative bacteria is mainly due to the production of efficient carbapenemases, ß-lactamases with a narrower spectrum may also contribute to resistance when combined with additional mechanisms. OXA-10-type class D ß-lactamases, previously shown to be weak carbapenemases, could represent such a case. In this study, two novel OXA-10 variants were identified as the sole carbapenem-hydrolyzing enzymes in meropenem-resistant enterobacteria isolated from hospital wastewater and found by next-generation sequencing to express additional ß-lactam resistance mechanisms. The new variants, OXA-655 and OXA-656, were carried by two related IncQ1 broad-host-range plasmids. Compared to the sequence of OXA-10, they both harbored a Thr26Met substitution, with OXA-655 also bearing a leucine instead of a valine in position 117 of the SAV catalytic motif. Susceptibility profiling of laboratory strains replicating the natural blaOXA plasmids and of recombinant clones expressing OXA-10 and the novel variants in an isogenic background indicated that OXA-655 is a more efficient carbapenemase. The carbapenemase activity of OXA-655 is due to the Val117Leu substitution, as shown by steady-state kinetic experiments, where the kcat of meropenem hydrolysis was increased 4-fold. In contrast, OXA-655 had no activity toward oxyimino-ß-lactams, while its catalytic efficiency against oxacillin was significantly reduced. Moreover, the Val117Leu variant was more efficient against temocillin and cefoxitin. Molecular dynamics indicated that Val117Leu affects the position 117-Leu155 interaction, leading to structural shifts in the active site that may alter carbapenem alignment. The evolutionary potential of OXA-10 enzymes toward carbapenem hydrolysis combined with their spread by promiscuous plasmids indicates that they may pose a future clinical threat.
Subject(s)
Anti-Bacterial Agents/chemistry , Enterobacteriaceae/genetics , beta-Lactam Resistance/genetics , beta-Lactamases/chemistry , Amino Acid Substitution , Anti-Bacterial Agents/metabolism , Anti-Bacterial Agents/pharmacology , Base Sequence , Catalytic Domain , Cefoxitin/chemistry , Cefoxitin/metabolism , Cefoxitin/pharmacology , Cloning, Molecular , Enterobacteriaceae/drug effects , Enterobacteriaceae/enzymology , Gene Expression , Hospitals , Humans , Hydrolysis , Isoenzymes/chemistry , Isoenzymes/genetics , Isoenzymes/metabolism , Kinetics , Meropenem/chemistry , Meropenem/metabolism , Meropenem/pharmacology , Microbial Sensitivity Tests , Models, Molecular , Oxacillin/chemistry , Oxacillin/metabolism , Oxacillin/pharmacology , Penicillins/chemistry , Penicillins/metabolism , Penicillins/pharmacology , Plasmids/chemistry , Plasmids/metabolism , Protein Binding , Protein Interaction Domains and Motifs , Protein Structure, Secondary , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Substrate Specificity , Wastewater/microbiology , beta-Lactamases/genetics , beta-Lactamases/metabolismABSTRACT
Evolution has provided environmental bacteria with a plethora of genes that give resistance to antibiotic compounds. Under anthropogenic selection pressures, some of these genes are believed to be recruited over time into pathogens by horizontal gene transfer. River sediment polluted with fluoroquinolones and other drugs discharged from bulk drug production in India constitute an environment with unprecedented, long-term antibiotic selection pressures. It is therefore plausible that previously unknown resistance genes have evolved and/or are promoted here. In order to search for novel resistance genes, we therefore analyzed such river sediments by a functional metagenomics approach. DNA fragments providing resistance to different antibiotics in E. coli were sequenced using Sanger and PacBio RSII platforms. We recaptured the majority of known antibiotic resistance genes previously identified by open shot-gun metagenomics sequencing of the same samples. In addition, seven novel resistance gene candidates (six beta-lactamases and one amikacin resistance gene) were identified. Two class A beta-lactamases, blaRSA1 and blaRSA2, were phylogenetically close to clinically important ESBLs like blaGES, blaBEL and blaL2, and were further characterized for their substrate spectra. The blaRSA1 protein, encoded as an integron gene cassette, efficiently hydrolysed penicillins, first generation cephalosporins and cefotaxime, while blaRSA2 was an inducible class A beta-lactamase, capable of hydrolyzing carbapenems albeit with limited efficiency, similar to the L2 beta-lactamase from Stenotrophomonas maltophilia. All detected novel genes were associated with plasmid mobilization proteins, integrons, and/or other resistance genes, suggesting a potential for mobility. This study provides insight into a resistome shaped by an exceptionally strong and long-term antibiotic selection pressure. An improved knowledge of mobilized resistance factors in the external environment may make us better prepared for the resistance challenges that we may face in clinics in the future.
Subject(s)
Carbapenems/metabolism , Geologic Sediments/microbiology , Metagenome , Water Pollutants, Chemical/analysis , beta-Lactam Resistance , beta-Lactamases/genetics , Anti-Bacterial Agents/pharmacology , Drug Industry , Industrial Waste/adverse effects , Metagenome/drug effects , Metagenome/genetics , Metagenomics , Rivers/microbiology , beta-Lactam Resistance/drug effects , beta-Lactam Resistance/geneticsABSTRACT
BACKGROUND: Metallo-ß-lactamases are bacterial enzymes that provide resistance to carbapenems, the most potent class of antibiotics. These enzymes are commonly encoded on mobile genetic elements, which, together with their broad substrate spectrum and lack of clinically useful inhibitors, make them a particularly problematic class of antibiotic resistance determinants. We hypothesized that there is a large and unexplored reservoir of unknown metallo-ß-lactamases, some of which may spread to pathogens, thereby threatening public health. The aim of this study was to identify novel metallo-ß-lactamases of class B1, the most clinically important subclass of these enzymes. RESULTS: Based on a new computational method using an optimized hidden Markov model, we analyzed over 10,000 bacterial genomes and plasmids together with more than 5 terabases of metagenomic data to identify novel metallo-ß-lactamase genes. In total, 76 novel genes were predicted, forming 59 previously undescribed metallo-ß-lactamase gene families. The ability to hydrolyze imipenem in an Escherichia coli host was experimentally confirmed for 18 of the 21 tested genes. Two of the novel B1 metallo-ß-lactamase genes contained atypical zinc-binding motifs in their active sites, which were previously undescribed for metallo-ß-lactamases. Phylogenetic analysis showed that B1 metallo-ß-lactamases could be divided into five major groups based on their evolutionary origin. Our results also show that, except for one, all of the previously characterized mobile B1 ß-lactamases are likely to have originated from chromosomal genes present in Shewanella spp. and other Proteobacterial species. CONCLUSIONS: This study more than doubles the number of known B1 metallo-ß-lactamases. The findings have further elucidated the diversity and evolutionary history of this important class of antibiotic resistance genes and prepare us for some of the challenges that may be faced in clinics in the future.
Subject(s)
Bacteria/enzymology , Genome, Bacterial , beta-Lactamases/genetics , beta-Lactamases/isolation & purification , Animals , Anti-Bacterial Agents/metabolism , Anti-Bacterial Agents/pharmacology , Bacteria/genetics , Bacteria/pathogenicity , Escherichia coli/drug effects , Escherichia coli/enzymology , Genomics/methods , Humans , Imipenem/metabolism , Imipenem/pharmacology , Markov Chains , Metagenomics/methods , Microbial Sensitivity Tests , Phylogeny , Plasmids/genetics , beta-Lactamases/classification , beta-Lactamases/metabolismABSTRACT
Dose optimization is required to increase carbapenem's efficacy against carbapenemase-producing isolates. Four clinical Klebsiella pneumoniae isolates were used: one susceptible to meropenem with minimum inhibitory concentration (MIC) 0.031 mg/L and 3 verona integron-borne metallo bete-lactamase-1-producing isolates with MICs 8, 16, and 128 mg/L. The human pharmacokinetics of short (0.5-h) and prolonged (3-h) infusion regimens of 1 g meropenem every 8 h were simulated in an in vitro pharmacokinetic-pharmacodynamic model. Time-kill curves were constructed for each isolate and dosing regimen, and the %T > MIC associated with maximal bactericidal activity was estimated. The percentage of pharmacodynamic target attainment for isolates with different MICs was calculated for 350 ICU, surgical, and internal medicine patients. The isolates with MIC ≤8 mg/L were killed with both dosing regimens. The %T > MIC corresponding to maximal bactericidal activity was â¼40%. The percentages of target attainment were >90%, 61%-83%, 23%-33%, and <3% with the short infusion regimen and >90%, 98%-99%, 55%-79%, and <5% with the prolonged infusion regimen for isolates with MIC ≤2, 4, 8, and ≥16 mg/L, respectively. The lowest target attainment rates were observed for the ICU patients and the highest for internal medicine patients. The prolonged infusion regimen was more effective than the short infusion regimen against isolates with MIC 4-8 mg/L.
Subject(s)
Anti-Bacterial Agents/administration & dosage , Klebsiella Infections/drug therapy , Klebsiella pneumoniae/drug effects , Thienamycins/administration & dosage , Adolescent , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/pharmacokinetics , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Equipment Design , Female , Humans , Infusion Pumps , Male , Meropenem , Middle Aged , Models, Biological , Thienamycins/pharmacokinetics , Thienamycins/pharmacology , Thienamycins/therapeutic use , Young AdultABSTRACT
VIM-producing Klebsiella pneumoniae isolates are usually associated with high MICs to carbapenems. Preclinical studies investigating the pharmacokinetic-pharmacodynamic (PK-PD) characteristics of carbapenems against these isolates are lacking. The in vitro antibacterial activity of meropenem against one WT and three VIM-producing K. pneumoniae clinical isolates (median MICs 0.031, 8, 16 and 128âmg l- 1) was studied in a dialysis-diffusion PK-PD model and verified in a thigh infection neutropenic animal model by testing selected strains and exposures. The in vitro PK-PD target associated with bactericidal activity was estimated and the target attainment for different dosing regimens was calculated with Monte Carlo analysis. The in vitro model was correlated with the in vivo data, with log10CFU/ml reduction of < 1 for the VIM-producing (MIC 16âmg l- 1) and >2 for the WT (MIC 0.031âmg l- 1) isolates, with %fâT >MIC 25 and 100%, respectively. The in vitro bactericidal activity for all isolates was associated with 40 % fâT>MIC and attained in >90% of cases with the standard 1âg q8 0.5âh infusion dosing regimen only for isolates with MICs up to 1âmg l- 1. For isolates with MICs of 2-8âmg l- 1, prolonged infusion regimens (4âh infusion q8 or 2âh infusion q4) of standard (1âg) and higher (2âg) doses or continuous infusion regimens (3-6âg) are required. For isolates with a MIC of 16âmg l- 1 the unconventional dosing regimen of 2âg as 2âh infusion q4 or 12âg continuous infusion will be required. Prolonged and continuous infusion regimens of meropenem may increase efficacy against VIM-producing K. pneumoniae isolates.
Subject(s)
Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/pharmacokinetics , Klebsiella Infections/microbiology , Klebsiella pneumoniae/drug effects , Thienamycins/pharmacology , Thienamycins/pharmacokinetics , beta-Lactamases/metabolism , Animals , Drug Resistance, Bacterial , Humans , Klebsiella Infections/drug therapy , Klebsiella pneumoniae/metabolism , Meropenem , Mice , Mice, Inbred ICR , Microbial Sensitivity Tests , Models, Biological , Monte Carlo Method , beta-Lactamases/geneticsSubject(s)
Bacterial Proteins/genetics , Carbapenems/pharmacology , Klebsiella Infections/drug therapy , Klebsiella pneumoniae/genetics , Polymorphism, Genetic , Porins/genetics , beta-Lactam Resistance/genetics , Bacterial Proteins/chemistry , DNA Mutational Analysis , Greece , Humans , Klebsiella Infections/genetics , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/enzymology , Microbial Sensitivity Tests , Multilocus Sequence Typing , Porins/chemistry , Sequence Analysis, ProteinABSTRACT
The performance of Oxoid Brilliance™ CRE Agar (BCRE), a new chromogenic medium designed for screening of carbapenem-resistant Enterobacteriaceae, was evaluated on a collection of clinical isolates of enterobacteria (n=175) and non-fermenters (n=55) with known ß-lactam resistance mechanisms and levels of susceptibility to carbapenems. BCRE supported the growth of 100 of 108 enterobacterial isolates that were non-susceptible to at least one carbapenem, whilst excluding 57 of the 67 carbapenem-susceptible isolates. The eight non-susceptible isolates that did not grow on BCRE were carbapenemase-producers with low carbapenem minimum inhibitory concentrations, mostly exhibiting non-susceptibility only to one carbapenem. In total, of 107 carbapenemase-producing enterobacteria that were included in the study, 16 did not grow, with most of them being either susceptible (n=8) or intermediate-susceptible (n=5) to carbapenems. Regarding the 10 carbapenem-susceptible enterobacteria that were not excluded by BCRE, 1 produced a carbapenemase and the rest possessed strong backgrounds of various other ß-lactam resistance mechanisms. The medium allowed growth of almost all carbapenem-resistant non-fermenting isolates; nevertheless, non-fermenters were clearly differentiated from Enterobacteriaceae by colony colour and morphology.
Subject(s)
Cattle Diseases/microbiology , Escherichia coli Infections/veterinary , Escherichia coli/enzymology , Mutation, Missense , beta-Lactamases/genetics , Animals , Cattle , Escherichia coli/drug effects , Escherichia coli/genetics , Escherichia coli/isolation & purification , Escherichia coli Infections/microbiology , Kinetics , Microbial Sensitivity Tests , Switzerland , beta-Lactamases/metabolism , beta-Lactams/pharmacologyABSTRACT
CMY-30 and CMY-42 are extended-spectrum (ES) derivatives of CMY-2. ES characteristics are due to substitutions of Gly (CMY-30) and Ser (CMY-42) for Val211 in the Ω-loop. To characterize the effects of 211 substitutions, we studied the interactions of CMY-2, -30, and -42 with boronic acid transition state inhibitors (BATSIs) resembling ceftazidime and cefotaxime, assessed thermal stability of the enzymes in their free forms and in complexes with BATSIs and oximino-ß-lactams, and simulated, using molecular dynamics (MD), the CMY-42 apoenzyme and the CMY-42 complexes with ceftazidime and the ceftazidime-like BATSI. Inhibition constants showed that affinities between CMY-30 and CMY-42 and the R1 groups of BATSIs were lower than those of CMY-2. ES variants also exhibited decreased thermal stability either as apoenzymes or in covalent complexes with oximino compounds. MD simulations further supported destabilization of the ES variants. Val211Ser increased thermal factors of the Ω-loop backbone atoms, as previously observed for CMY-30. The similar effects of the two substitutions seemed to be due to a less-constrained Tyr221 likely inducing concerted movement of elements at the edges of the active site (Ω-loop-Q120 loop-R2 loop/H10 helix). This inner-protein movement, along with the wider R1 binding cleft, enabled intense vibrations of the covalently bound ceftazidime and ceftazidime-like BATSIs. Increased flexibility of the ES enzymes may assist the productive adaptation of the active site to the various geometries of the oximino substrates during the reaction (higher frequency of near-attack conformations).
Subject(s)
Boronic Acids/metabolism , Escherichia coli Proteins/metabolism , Escherichia coli , beta-Lactamases/metabolism , beta-Lactams/metabolism , Amino Acid Substitution , Boronic Acids/chemistry , Cephalosporin Resistance/genetics , Cephalosporinase/chemistry , Cephalosporinase/metabolism , Cephalosporins/chemistry , Cephalosporins/metabolism , Cephalosporins/pharmacology , Citrobacter freundii/enzymology , Escherichia coli/drug effects , Escherichia coli/enzymology , Escherichia coli/genetics , Escherichia coli Proteins/chemistry , Molecular Dynamics Simulation , Protein Structure, Tertiary , beta-Lactamases/chemistry , beta-Lactams/chemistryABSTRACT
CMY-30, a naturally occurring class C ß-lactamase differing from the Citrobacter freundii-derived CMY-2 by a Val211Gly substitution in the Ω-loop, exhibits increased hydrolytic efficiency against ceftazidime and cefotaxime. Kinetic constants of CMY-2 and CMY-30 against the latter substrates suggested that the improved efficiency of the Gly211 variant was due to an increase in k(cat). The structural basis of the increased turn-over rates of oxyimino-cephalosporins caused by Val211Gly was studied using 5 ns molecular dynamics simulations of CMY-2 and CMY-30 in their free forms and in covalent complexes with ceftazidime (acyl-enzyme) as well as a boronic acid analogue of ceftazidime (deacylation transition state). Analysis of thermal factors indicated that Val211Gly increased the flexibility of the Ω-loop/H7-helix and the Q120-loop formed by amino acids 112-125, and also altered the vibrations of the H10-helix/R2-loop. Structural elements containing the catalytic residues remained relatively rigid except Tyr150 in acyl-enzyme species. Regions exhibiting altered flexibility due to the substitution appear to move in a concerted manner in both enzymes. This movement was more intense in CMY-30 and also at directions different to those observed for CMY-2. Additionally, it appeared that the Val211Gly increased the available space for the accommodation of the R1 side chain of ceftazidime. These findings are likely associated with the significantly increased vibrations of the bound compounds observed in CMY-30 complexes. Therefore, the extended spectrum properties of CMY-30 seem to arise through a complex process implicating changes in protein movement and in the mode of substrate accommodation.
Subject(s)
Cephalosporins/metabolism , beta-Lactamases/genetics , Amino Acid Substitution , Hydrolysis , Kinetics , Models, Molecular , Molecular Dynamics Simulation , Protein Structure, Secondary , beta-Lactamases/metabolismABSTRACT
We isolated a clinical Escherichia coli strain with an antimicrobial resistance phenotype characteristic for the expression of an AmpC beta-lactamase. Molecular methods revealed a novel, plasmid-localized variant of CMY-2 with a substitution of valine 231 for serine (V231S), which was designated CMY-42. Like the CMY-2-like AmpC beta-lactamase CMY-30, carrying the substitution V231G, CMY-42 displayed increased activity toward expanded spectrum cephalosporins. This finding supports the hypothesis that a bulky side chain at position 231 (Ambler's position 211) may pose a steric clash with certain cephalosporins hindering the access of the AmpC beta-lactamase; however, additional phenomena may account for the observed hydrolytic properties.
Subject(s)
Anti-Bacterial Agents/pharmacology , Cephalosporins/pharmacology , Drug Resistance, Bacterial/genetics , Escherichia coli Infections/microbiology , Escherichia coli Proteins/genetics , Escherichia coli , Plasmids/genetics , Surgical Wound Infection/microbiology , beta-Lactamases/genetics , Drug Resistance, Bacterial/drug effects , Escherichia coli/genetics , Escherichia coli/growth & development , Escherichia coli/isolation & purification , Escherichia coli Infections/drug therapy , Escherichia coli Infections/genetics , Escherichia coli Proteins/metabolism , Humans , Molecular Sequence Data , Plasmids/metabolism , Serine/genetics , Serine/metabolism , Surgical Wound Infection/drug therapy , Surgical Wound Infection/genetics , Valine/genetics , Valine/metabolism , beta-Lactamases/metabolismABSTRACT
In GES-type ß-lactamases, positions 104 and 170 are occupied by Glu or Lys and by Gly, Asn, or Ser, respectively. Previous studies have indicated an important role of these amino acids in the interaction with ß-lactams, although their precise role, especially that of residue 104, remains uncertain. In this study, we constructed GES-1 (Glu104, Gly170), GES-2 (Glu104, Asn170), GES-5 (Glu104, Ser170), GES-6 (Lys104, Ser170), GES-7 (Lys104, Gly170), and GES-13 (Lys104, Asn170) by site-specific mutagenesis and compared their hydrolytic properties. Isogenic comparisons of ß-lactam resistance levels conferred by these GES variants were also performed. Data indicated the following patterns: (i) Lys104-containing enzymes exhibited enhanced hydrolysis of oxyimino-cephalosporins and reduced efficiency against imipenem in relation to enzymes possessing Glu104, (ii) Asn170-containing enzymes showed reduced hydrolysis rates of penicillins and older cephalosporins, (iii) Ser170 enabled GES to hydrolyze cefoxitin efficiently, and (iv) Asn170 and Ser170 increased the carbapenemase character of GES enzymes but reduced their activity against ceftazidime. Molecular dynamic simulations of GES apoenzyme models, as well as construction of GES structures complexed with cefoxitin and an achiral ceftazidime-like boronic acid, provided insights into the catalytic behavior of the studied mutants. There were indications that an increased stability of the hydrogen bonding network of Glu166-Lys73-Ser70 and an altered positioning of Trp105 correlated with the substrate spectra, especially with acylation of GES by imipenem. Furthermore, likely effects of Ser170 on GES interactions with cefoxitin and of Lys104 on interactions with oxyimino-cephalosporins were revealed. Overall, the data unveiled the importance of residues 104 and 170 in the function of GES enzymes.
Subject(s)
Computational Biology/methods , beta-Lactamases/chemistry , beta-Lactamases/metabolism , Ampicillin/pharmacology , Escherichia coli/drug effects , Escherichia coli/enzymology , Hydrogen Bonding , Microbial Sensitivity Tests , Mutagenesis, Site-Directed , Protein Structure, Secondary , Ticarcillin/pharmacology , beta-Lactamases/geneticsABSTRACT
CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase, was derived by mutagenesis. The hydrolytic efficiency of CMY-30 against expanded-spectrum cephalosporins was higher than that of CMY-2 due to increased k(cat) values. Findings indicate a role of the Omega loop residue 211 in determining the substrate specificities of CMYs also corroborated by modeling studies.